This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Adenovirus-CD35, Ad-ISF35, Immune Stimulatory Factor 35
Description: Memgen's recombinant Immune Stimulatory Factor 35 (ISF35) molecule is a novel CD40 binding protein engineered to be an immune-stimulant that maximizes the clinical activity of the molecule while eliminating the toxicities associated with its parent molecule CD154 (CD40-ligand). ISF35's high therapeutic index (activity versus toxicity) is due to the delivery of this molecule in a membrane-bound form that is not cleaved into toxic metabolites. As a single agent in pre-clinical studies, ISF35 has demonstrated activity against B cell leukemias and lymphomas resulting in acute and long lasting responses against these diseases.
Deal Structure: Memgen licensed the technology for the ISF35 molecule from UCSD.
Additional information available to subscribers only: